Answers are grounded in this paper and cite their sources.
Abstract ID 95704 Poster Board 261 Acute myeloid leukemia (AML) overall survival rates remain unacceptably low. Hence, new drugs are needed to improve overall survival. The imipridone family of anticancer agents have shown efficacy against various cancers, including AML. Thus, we investigated the efficacy and mechanism of action of the novel imipridone, ONC213, in preclinical AML models. AML cell lines and primary patient samples showed varying degrees of sensitivity to ONC213. However, ONC213 uniformly suppressed the clonogenicity of primary AML patient samples (n=6, 500 nM reduced colony numbers to <5%), suggesting it targets leukemic progenitor/stem cells. Ex vivo treatment of two primary patient samples with ONC213 significantly reduced in vivo engraftment to the levels observed in non-tumor bearing mice. Treatment of an AML patient-derived xenograft model potently reduced leukemia stem cells (hCD45+/hCD34+/hCD38-/hCD123+) by 70%. Notably, ONC213 did not induce apoptosis in peripheral blood mononuclear cells from healthy controls and had no significant effect on clonogenicity of normal CD34+ hematopoietic progenitor cells. Seahorse analysis revealed that ONC213 reduces mitochondrial respiration. Further, forcing AML cells to rely on oxidative phosphorylation (OXPHOS), by culturing cells with galactose instead of glucose, significantly increased ONC213-induced apoptosis, indicating that OXPHOS-reliant AML cells are more sensitive to ONC213. Due to the relationship between the citric acid (TCA) cycle and OXPHOS, we measured 6 TCA cycle intracellular metabolites and found that α-ketoglutarate was the only metabolite that was significantly increased (p<0.01, 2.5- to 5-fold increase) upon ONC213 treatment. Consistent with this, ONC213 also strongly reduced α-ketoglutarate dehydrogenase (α-KGDH) activity. CRISPR enabled genetic "Fitness" survival assays on cell populations with varying degrees of deleted OGDH (encodes α-KGDH) confirmed that α-KGDH was required to survive an ONC213 challenge. RNA-seq analysis of AML cell lines revealed 100 commonly upregulated genes that distinguished ONC213-treated from untreated cells. Interactive pathway analysis revealed a mitochondrial stress gene signature. ONC213 suppressed de novo protein synthesis. Notably, ONC213 reduced Mcl-1 levels, and Mcl-1 overexpression confirmed its role in ONC213 sensitivity. Taken together, we show that ONC213 suppression of α-KGDH activity and mitochondrial respiration elicits a mitochondrial stress response that is coupled to inhibition of de novo protein synthesis and decreased Mcl-1 protein levels. Therefore, ONC213 suppression of α-KGDH activity, decreased OXPHOS and reduced Mcl-1 level seem to lead to death of OXPHOS-reliant AML cells. That ONC213 kills AML progenitors and leukemic stem cells (cells that often drive relapse) supports the further development of this candidate therapeutic. Funding Information: Kids Without Cancer, Children's Hospital of Michigan Foundation, Ring Screw Textron Endowed Chair in Pediatric Cancer Research (JWT), and Ronald N. Buick Chair in Oncology Research (ADS). The Animal Model and Therapeutics Evaluation Core, Pharmacology Core, and Genomics Core are supported, in part, by NIH Center Grant P30 CA022453 to the Karmanos Cancer Institute at Wayne State University. The Cell & Tissue Imaging Center is supported by the American Lebanese Syrian Associated Charities, NCI P30 CA021765 (SJCRH), and NIH grants R01 CA194057, CA21865, and CA96832 to SJCRH.
No takes yet. Share an insight, caveat, or question.
Fukuda et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: